Search Results - "Alvarez, Delia"

Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105 by Liu, Yingmiao, Starr, Mark D, Brady, John C, Rushing, Christel, Pang, Herbert, Adams, Bonne, Alvarez, Delia, Theuer, Charles P, Hurwitz, Herbert I, Nixon, Andrew B

“…TRC105 is an anti-endoglin antibody currently being tested in combination with VEGF inhibitors. In the phase Ib trial, 38 patients were treated with both…”
Get full text

Shedding light on the mitochondrial matrix through a functional membrane transporter by Blázquez-Moraleja, Alberto, Sáenz-de-Santa María, Ines, Chiara, María D., Álvarez-Fernández, Delia, García-Moreno, Inmaculada, Prieto-Montero, Ruth, Martínez-Martínez, Virginia, López Arbeloa, Iñigo, Chiara, Jose Luis

“…The first fluorescent probes that are actively channeled into the mitochondrial matrix by a specific mitochondrial membrane transporter in living cells have…”
Get full text

A general modular approach for the solubility tagging of BODIPY dyes by Blázquez-Moraleja, Alberto, Álvarez-Fernández, Delia, Prieto Montero, Ruth, García-Moreno, Inmaculada, Martínez-Martínez, Virginia, Bañuelos, Jorge, Sáenz-de-Santa-María, Inés, Chiara, María D., Chiara, Jose Luis

“…We describe a general and practical strategy for the direct one-step incorporation of a tunable solubility module at the boron atom of F-BODIPY dyes. The…”
Get full text

A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer by ROSEN, Lee S, HURWITZ, Herbert I, THEUER, Charles P, LEIGH, Bryan R, GORDON, Michael S, WONG, Michael K, GOLDMAN, Jonathan, MENDELSON, David S, FIGG, William D, SPENCER, Shawn, ADAMS, Bonne J, ALVAREZ, Delia, SEON, Ben K

“…TRC105 is a chimeric IgG1 monoclonal antibody that binds CD105 (endoglin). This first-in-human, phase I, open-label study assessed safety, pharmacokinetics,…”
Get full text

Moodle: Aprovechamiento de herramientas en el centro universitario del norte by Ceballos Macías, Jorge Daniel, Alvarez Haro, Delia Cecilia, García Álvarez, Luis Enrique

“…El Centro Universitario del Norte (CUNorte) de la Universidad de Guadalajara (U. de G.), tiene una modalidad educativa presencial con apoyo en las tecnologías…”
Get full text

Comparison of vis-NIR spectral signatures of soils cultivated with sugarcane (Sacharum sp.) in the Villa Clara province by Ahmed Chacón-Iznaga, Miguel Rodríguez-Orozco, Edith Aguila-Alcantara, Ariany Colás-Sánchez, Diana González-Aguiar, Delia Luisa Alvarez-Vázquez, Josse de Baerdemaeker, Wouter Saeys

“…The objective of this research was to compare the spectral signature of two soil types, Cambisol and Vertisol, cultivated with sugarcane in the Villa Clara…”
Get full text

KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRAS G12C mutation by Mok, Tony S. K., Lawler, William E., Shum, Merrill Kingman, Dakhil, Shaker R., Spira, Alexander I., Barlesi, Fabrice, Reck, Martin, Garassino, Marina Chiara, Spigel, David R., Alvarez, Delia, Kheoh, Thian, Paxton, William, Chao, Richard C., Felip, Enriqueta

“…Abstract only TPS9129 Background: Despite significant advances in chemotherapy and immunotherapy for advanced NSCLC, the majority of pts ultimately develop…”
Get full text

Cellulolytic fungi populations in stubble and soil as affected by agricultural management practices by Luque, A.G, Pioli, R, Bonel, B, Alvarez, D.P

“…The aim of this study was to evaluate the effects of different agricultural management practices on the dynamics of cellulolytic fungi populations. The…”
Get full text

An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer by Gordon, Michael S, Robert, Francisco, Matei, Daniela, Mendelson, David S, Goldman, Jonathan W, Chiorean, E Gabriela, Strother, Robert M, Seon, Ben K, Figg, William D, Peer, Cody J, Alvarez, Delia, Adams, Bonne J, Theuer, Charles P, Rosen, Lee S

“…Endoglin, an endothelial cell membrane receptor expressed on angiogenic tumor vessels, is essential for angiogenesis and upregulated in the setting of VEGF…”
Get full text

La educación no formal: una herramienta importante para la formación del estudiante de medicina by De Benedictis Serrano, Ginno Alessandro, Camel Calderon, Orianna Gabriela, Sequera Torres, Nahir José, Alvarez Romero, Esbery Delia

“…El impacto de la educación desde sus diferentes aristas es invaluable, especialmente en el ámbito universitario y resaltado en la carrera de medicina, por lo…”
Get full text

Phase II study of sitravatinib in combination with nivolumab in patients with advanced or metastatic urothelial carcinoma (UC) after checkpoint inhibitor therapy (CIT) by Doshi, Gurjyot K., Vogelzang, Nicholas J., Richards, Donald A., Chong, Daniel, Shaffer, David R., Nordquist, Luke T., Picus, Joel, Alvarez, Delia, Der-Torossian, Hirak, Christensen, James, Yorio, Jeffrey Thomas

“…Abstract only TPS498 Background: Combination therapy with agents targeting molecular and cellular mechanisms of CIT resistance is a rational approach to…”
Get full text

Phase III trial of sitravatinib plus nivolumab vs. docetaxel for treatment of NSCLC after platinum-based chemotherapy and immunotherapy (SAPPHIRE) by Percent, Ivor John, Reynolds, Craig H., Konduri, Kartik, Whitehurst, Matthew Thomas, Nidhiry, Emmanuel A., Yanagihara, Ronald H., Nagasaka, Misako, Schreeder, Marshall T, Uyeki, James, Azzi, Georges, Pachipala, Krishna Kishore, Comer, Jason C., Lerner, Rachel E., Leal, Ticiana, Alvarez, Delia, Neuteboom, Saskia T.C., Reddinger, Natasha, yan, xiaohong, Shazer, Ronald L., Waterhouse, David Michael

“…Abstract only TPS9635 Background: Sitravatinib is an oral spectrum-selective tyrosine kinase inhibitor that targets the TAM (TYRO3/AXL/MERTK) and split…”
Get full text

A new algorithm for feature selection based on rough sets theory by Yailé Caballero, Delia Álvarez, Analay Baltá, Rafael Bello, María García

“…Rough Sets Theory has opened new trends for the development of data analysis techniques. In this theory, the notion of reduct is very significant, but…”
Get full text

Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS) by Jones, Robin Lewis, Attia, Steven, Mehta, Cyrus R., Liu, Lingyun, Sankhala, Kamalesh Kumar, Robinson, Steven Ian, Ravi, Vinod, Penel, Nicolas, Stacchiotti, Silvia, Tap, William D., Alvarez, Delia, Yocum, Richard, Theuer, Charles P., Maki, Robert G.

“…Abstract only TPS11081 Background: AAS is an aggressive soft tissue sarcoma (STS) of endothelial cell origin with an expected median overall survival of 8-12…”
Get full text

Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy by Liu, Yingmiao, Yuan, Zhenhua, Zhang, Dadong, Starr, Mark D., Brady, John C., Jivani, Manoj A., Adams, Bonne J., Alvarez, Delia, Attia, Steven, Choueiri, Toni K., Theuer, Charles P., Owzar, Kouros, Hurwitz, Herbert, Nixon, Andrew B.

“…Abstract only 11546 Background: TRC105, an endoglin-targeting monoclonal antibody with anti-angiogenic and anti-tumor activity, is being evaluated in multiple…”
Get full text

TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma by Ravi, Vinod, Brohl, Andrew Scott, Chawla, Sant P., Attia, Steven, Riedel, Richard F., Liebner, David A., Thornton, Katherine Anne, Basu Mallick, Atrayee, Mehta, Cyrus R., Liu, Lingyun, Alvarez, Delia, Theuer, Charles P., Robinson, Steven Ian, Penel, Nicolas, Stacchiotti, Silvia, Tap, William D., Jones, Robin Lewis, Maki, Robert G.

“…Abstract only…”
Get full text

Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS) by Ravi, Vinod, Brohl, Andrew Scott, Chawla, Sant P., Attia, Steven, Riedel, Richard F., Liebner, David A., Thornton, Katherine Anne, Basu Mallick, Atrayee, Davis, Darren W., Cervantes, Mario, Liu, Wen, Zhu, Keyi, Alvarez, Delia, Theuer, Charles P., Robinson, Steven Ian, Penel, Nicolas, Stacchiotti, Silvia, Tap, William D., Jones, Robin Lewis, Maki, Robert G.

“…Abstract only…”
Get full text

A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS) by Attia, Steven, Riedel, Richard F., Robinson, Steven Ian, Conry, Robert Martin, Sankhala, Kamalesh Kumar, Seon, Ben K., Alvarez, Delia, Adams, Bonne J., Theuer, Charles P., Maki, Robert G.

“…Abstract only…”
Get full text

A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS) by Attia, Steven, Sankhala, Kamalesh Kumar, Riedel, Richard F., Robinson, Steven Ian, Conry, Robert Martin, Boland, Patrick McKay, Barve, Minal A., Fritchie, Karen, Seon, Ben K., Alvarez, Delia, Adams, Bonne J., Shazer, Ronald L., Theuer, Charles P., Maki, Robert G.

“…Abstract only…”
Get full text

Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial by Liu, Yingmiao, Clarke, Jeffrey Melson, Starr, Mark D., Brady, John C., Pang, Herbert, Rushing, Christel, Alvarez, Delia, Adams, Bonne J., Theuer, Charles P., Hurwitz, Herbert, Nixon, Andrew B.

“…Abstract only…”
Get full text